Interstitial Lung Disease (ILD) and Pneumonitis

ILD and pneumonitis, including Grade 5 cases, have been reported with ENHERTU; the majority were Grade 1 or 2 (n=16/22)1,2,a,b

  • In clinical studies, of the 234 patients with HER2+ unresectable or mBC treated with ENHERTU
    5.4 mg/kg, ILD occurred in 9% of patients (n=22/234)1,2
    • Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients (n=6/234)1
  • Median time to first onset was 4.1 months (range: 1.2-8.3)1

aILD includes events that were adjudicated as ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, alveolitis.1 bGrade 5=fatal cases.2

aILD includes events that were adjudicated as ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, alveolitis.1 bGrade 5=fatal cases.2

Talk with your patients about the potential benefits and risks of treatment with ENHERTU

Symptom identification and investigation at the first sign of ILD/pneumonitis are key to diagnosis and monitoring

Signs and symptoms of ILD/pneumonitis1

  • Cough
  • Dyspnea
  • Fever
  • New or worsening respiratory symptoms

Promptly investigate evidence of ILD/pneumonitis3

  • Evaluation may include:
    • High-resolution CT
    • Pulmonologist consultation
    • Blood culture and CBC
    • Consider bronchoscopy
    • Arterial blood gases if clinically indicated
  • All events of ILD/pneumonitis, regardless of severity or seriousness, should be followed until resolution including after drug discontinuation

Investigation may be prompted by incidental findings on routine scans when checking for progression or symptomatic findings; diagnosis of ILD/pneumonitis requires exclusion of other causes.

For asymptomatic ILD (Grade 1)1

  • Consider corticosteroid treatment (eg, ≥0.5 mg/kg/ day prednisolone or equivalent)
  • Interrupt ENHERTU until resolved to Grade 0, then:

For symptomatic ILD (Grade 2 or greater)1

  • Promptly initiate systemic corticosteroid treatment (eg, ≥1 mg/kg/day prednisolone or equivalent)
    • Continue for at least 14 days followed by gradual taper for at least 4 weeks
  • Permanently discontinue ENHERTU in patients who are diagnosed with any symptomatic ILD/pneumonitis

Talk to your patients to raise awareness and help identify symptoms1

Nurse chat bubble icon
  • Advise patients to contact their healthcare provider immediately for any of the symptoms shown above
  • Inform patients of the risks of severe, life-threatening, or fatal ILD
  • Advise patients to read the FDA-approved patient labeling:
    Download the Medication Guide

Potential questions to ask your patients to help with identification of ILD4,5

  • Have you been coughing recently? Is it a dry cough?
  • Have you had any shortness of breath, especially during or after physical activity?
  • Have you experienced any new breathing or respiratory problems?
  • If you already have respiratory problems, have they gotten worse?
  • Have you had a fever?
  • Have you been feeling tired?
  • Have you lost weight?

Review information for these other potential treatment risks:

Get ENHERTU Resources for You and Your Practice

Download icon
ENHERTU Dosage & Administration and Recommendations for Adverse Reactions Guide
Email icon
Ready to learn more about ENHERTU?
CBC, complete blood count; CT, computed tomography; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer.